Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | F2 | P00734 | 2/20 | 0.66 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.66 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.66 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 10/20 | 0.60 |
| ▸ | CA2 | P00918 | 10/20 | 0.60 |
| ▸ | CA5A | P35218 | 10/20 | 0.60 |
| ▸ | CA5B | Q9Y2D0 | 10/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15172850 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL1696817 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL2385301 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL2387335 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL5442172 | 1.00 | KMT2A (0.68) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL1362019 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL12705857 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL10000728 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL5960692 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 | |
| SCHEMBL863312 | 0.85 | KMT2A (0.70) | KMT2AF2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108963389-B | Gelable system for lithium-air battery and preparation method and application thereof | 北京师范大学 | 2020-11-13 | — | — | CN | claimed |
| EP-3637525-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND MANUFACTURING METHOD THEREFOR | Beijing Normal University (CN) | 2020-04-15 | — | — | EP | claimed |
| EP-3637524-A1 | GELATINIZED SYSTEM AND APPLICATIONS IN LITHIUM AIR BATTERY, SUPER CAPACITOR OR CAPACITOR BATTERY IN ORGANIC SYSTEM | Beijing Normal University (CN) | 2020-04-15 | — | — | EP | claimed |
| US-20200099090-A1 | FLEXIBLE ALL-SOLID-STATE LITHIUM-ION SECONDARY BATTERY AND PREPARATION METHOD THEREOF | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | claimed |
| US-20200099097-A1 | GELABLE SYSTEM AND USES THEREOF IN LITHIUM-AIR BATTERIES, ORGANIC SUPERCAPACITORS OR CAPACITOR BATTERIES | BEIJING NORMAL UNIVERSITY (CN) | 2020-03-26 | — | — | US | claimed |
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-12-17 | — | — | US | disclosed |
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-07-09 | — | — | US | disclosed |
| US-20240208922-A1 | A TRIFLUOROMETHYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF | STUDIENGESELLSCHAFT KOHLE GGMBH (DE) | 2024-06-27 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| US-11773058-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2023-10-03 | — | — | US | disclosed |
| WO-2023083343-A1 | POLYCYCLIC COMPOUNDS AND METHODS THEREOF | HEPAITECH (BEIJING) BIOPHARMA TECHNOLOGY CO., LTD. (CN) | 2023-05-19 | — | — | WO | disclosed |
| US-20070010676-A1 | Stereospecific enrichment of heterocyclic enantiomers | R.T. ALAMO VENTURES I, LLC | 2007-01-11 | — | — | US | disclosed |
| US-7084275-B2 | Stereospecific enrichment of heterocyclic enantiomers | R. T. ALAMO VENTURES I, LLC (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
| EP-1082127-B1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1BETA CONVERTING ENZYME | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040215016-A1 | Stereospecific enrichment of heterocyclic enantiomers | R.T. ALAMO VENTURES I, LLC | 2004-10-28 | — | — | US | disclosed |
| US-6649764-B2 | Racemization of flusequinan using triphenylphosphine and 10-camphorsulfonyl-oxaziridine to form racemic mixtures | R. T. ALAMO VENTURES I, LLC | 2003-11-18 | — | — | US | disclosed |
| US-20030120075-A1 | Stereospecific enrichment of heterocyclic enantiomers | R.T. ALAMO ADVENTURES I, LLC | 2003-06-26 | — | — | US | disclosed |
| US-20020052521-A1 | Ifosfamide, analogues thereof and their preparation | BRENNAN JOSEPH JOHN (IE) | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030879-B2 | Sulfonyl acetamides as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | KMT2A 2252/4885F2 4541/4885PRSS1 503/4885 |
| US-11773058-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, NLRP1 | KMT2A 3406/4885F2 3939/4885PRSS1 1390/4885 |
| US-20070010676-A1 | Stereospecific enrichment of heterocyclic enantiomers | CBR3, CBR1, QDPR | KMT2A 3308/4885F2 4715/4885PRSS1 3585/4885 |
| US-20240208922-A1 | A TRIFLUOROMETHYL THIANTHRENIUM COMPOUND, PROCESS FOR PREPARING THE SAME AND THE USE THEREOF | CYP4F3, GTF3C3, GTF3C4 | KMT2A 1991/4885F2 163/4885PRSS1 3609/4885 |
| US-20020052521-A1 | Ifosfamide, analogues thereof and their preparation | NAP1L1, WHR1, NR2E3 | KMT2A 3167/4885F2 3368/4885PRSS1 4223/4885 |
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | HTR2B, OPRD1, HTR1B | KMT2A 4182/4885F2 307/4885PRSS1 858/4885 |
| US-20040215016-A1 | Stereospecific enrichment of heterocyclic enantiomers | CBR3, POR, CBR1 | KMT2A 3103/4885F2 4694/4885PRSS1 3447/4885 |
| US-20030120075-A1 | Stereospecific enrichment of heterocyclic enantiomers | CBR3, POR, CBR1 | KMT2A 3103/4885F2 4694/4885PRSS1 3447/4885 |
| US-12168653-B2 | Sulfonamide derivates as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | KMT2A 3199/4885F2 3758/4885PRSS1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.